Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 4/20 | 0.31 |
| ▸ | THRB | P10828 | 3/20 | 0.31 |
| ▸ | CTSA | P10619 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6693924 | 0.84 | ATM (0.39) | RORCTHRBATMLMNAALDH1A1 | |
| SCHEMBL6694776 | 0.81 | THRA (0.35) | THRB | |
| SCHEMBL6689993 | 0.78 | RORC (0.48) | RORCTHRB | |
| SCHEMBL6698228 | 0.78 | BCL6 (0.38) | RORCTHRBLPAR1MEN1ALDH1A1 | |
| SCHEMBL6694237 | 0.76 | LMNA (0.34) | RORCTHRBCTSALPAR1LMNA | |
| SCHEMBL6692440 | 0.68 | THRB (0.36) | RORCTHRBLMNASMN1; SMN2MEN1 | |
| SCHEMBL6691529 | 0.66 | LMNA (0.34) | THRBLMNASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL6693919 | 0.66 | RORC (0.45) | RORCTHRB | |
| SCHEMBL6695983 | 0.66 | CA12 (0.39) | THRBLMNASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL6689854 | 0.66 | L3MBTL1 (0.39) | RORCTHRBLMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747048-B2 | TREATING DISEASES OR DISORDERS ASSOCIATED WITH METABOLISM DYSFUNCTION OR WHICH ARE DEPENDENT UPON THE EXPRESSION OF A T3 REGULATED GENE, | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-08 | — | — | US | disclosed |
| US-20040039028-A1 | Pyridine-based thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039028-A1 | Pyridine-based thyroid receptor ligands | TSHR, THRB, THRA | RORC 173/4885THRB 2/4885CTSA 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.